News About: Pharm. Affairs
Emergence of generics in the ‘Nexium’ market suffered by modified drugs
Patent expiration has completely changed the dynamics of the market of ‘Nexium,’ a peptic ulcer treatment. Both the original and its incrementally modified drugs were not able to avoid downtrends.
The phenomenon is i...
Daewoong’s patent trial for ezetimibe while the patent is expiring in 2 months
Daewoong Pharmaceutical has attracted attention as filing a patent lawsuit for ‘ezetimibe,’ a substance for the MSD’s hyperlipidemia treatment, which will be expired in 2 months.
Ezetimibe is a substance contained in...
Gardasil and Cervarix are accepted for Cervical Cancer Vaccination Business
‘Gardasil’ and ‘Cervarix’ were selected as supporting vaccines for the cervical cancer vaccination and health consultation business which will be enforced from this June.
According to the industry concerned, the ‘HPV...
Vaccine market of KRW 700 billion grows 8% annually, focused by premium vaccines
The vaccine market showing the size of KRW 700 billion was anticipated to have a high chance to become a blue ocean in the future as drawing an average 8% raising curve annually.
The industry expects the market, whic...
Protected by Patent-Linkage System, door of ‘Micardis Plus’ generic market opens
Domestic medium pharmaceutical companies have succeeded in avoiding the formulation patent of Micardis Plus(Boehringer Ingelheim), an antihypertensive complex.
The patent has been an obstacle for its generics to ente...
“Domestic orphan drugs are welcomed,” proving their technology
Development of orphan disease treatments has been accelerated. As announcing to extend the health insurance benefit standards for orphan diseases, the Korean government is also expected to quicken the similar movement...
Will ‘Drug Pricing System Consultative Group’ make corrective measures for drug pricing system?
In order to improve the unreasonable drug pricing system, the ‘Drug Pricing System Consultative Group’ will have the first meeting today(3rd).
The group, formed by the Ministry of Health and Welfare(MOHW), will discu...
Will the Supect’s insurance benefit end the cruelty of domestic anticancer drugs?
A chronic myeloid leukemia(CML) treatment, ‘Supect(generic name: radotinib)’ has drawn attention if it would end the cruelty of domestic anticancer drugs as approved as a primary treatment with the health insurance be...
Shrunk NSAIDs market led by domestic drugs
The domestic osteoarthritis treatment market led by Pfizer Pharmaceuticals Korea’s ‘Celebrex’ has quickly been depressed.
The patent expiration of the leading product, Celebrex, and the increased prescriptions of NSA...
4-way competition in the Novel Oral Anticoagulant(NOAC) market
Competition is expected to be fiercer in the rapidly growing NOAC market.
As Daiichi Sankyo launched Lixiana with the insurance benefit on the 1st of February, the 3-way competition among Xarelto, Pradaxa and Eliquis...
